
Investing.com – France stocks were higher after the close on Monday, as gains in the Healthcare, Oil&Gas and Consumer Goods sectors led shares higher.
At the close in Paris, the CAC 40 gained 0.11%, while the SBF 120 index gained 0.09%.
The best performers of the session on the CAC 40 were Sanofi SA (EPA:SASY), which rose 0.56% or 0.50 points to trade at 89.76 at the close. Meanwhile, Hermes International SCA (EPA:HRMS) added 0.42% or 8.00 points to end at 1,918.80 and Compagnie de Saint Gobain SA (EPA:SGOB) was up 0.41% or 0.27 points to 66.66 in late trade.
The worst performers of the session were Teleperformance SE (EPA:TEPRF), which fell 1.53% or 2.05 points to trade at 132.05 at the close. ArcelorMittal SA (AS:MT) declined 0.85% or 0.22 points to end at 25.68 and Renault SA (EPA:RENA) was down 0.65% or 0.24 points to 36.91.
The top performers on the SBF 120 were Voltalia SA (EPA:VLTSA) which rose 3.99% to 10.42, Solutions 30 SE (EPA:S30) which was up 3.25% to settle at 2.67 and Elior Group (EPA:ELIOR) which gained 2.73% to close at 2.93.
The worst performers were Clariane SE (EPA:CLARI) which was down 3.14% to 2.40 in late trade, Valneva (EPA:VLS) which lost 2.20% to settle at 4.72 and X Fab Silicon Foundries EV (EPA:XFAB) which was down 1.83% to 10.18 at the close.
Falling stocks outnumbered advancing ones on the Paris Stock Exchange by 0 to 0.
The CAC 40 VIX, which measures the implied volatility of CAC 40 options, was unchanged 0.00% to 18.96 a new 52-week high.
Gold Futures for February delivery was down 0.56% or 11.70 to $2,071.80 a troy ounce. Elsewhere in commodities trading, Crude oil for delivery in February fell 0.61% or 0.44 to hit $71.33 a barrel, while the March Brent oil contract fell 0.10% or 0.08 to trade at $77.07 a barrel.
EUR/USD was unchanged 0.00% to 1.10, while EUR/GBP unchanged 0.50% to 0.87.
The US Dollar Index Futures was up 0.15% at 101.06.
Begin trading today! Create an account by completing our form
At One Financial Markets we are committed to safeguarding your privacy.
Please see our Privacy Policy for details about what information is collected from you and why it is collected. We do not sell your information or use it other than as described in the Policy.
Please note that it is in our legitimate business interest to send you certain marketing emails from time to time. However, if you would prefer not to receive these you can opt-out by ticking the box below.
Alternatively, you can use the unsubscribe link at the bottom of the Demo account confirmation email or any subsequent emails we send.
By completing the form and downloading the platform you agree with the use of your personal information as detailed in the Policy.